Last reviewed · How we verify
Liberal Red blood cell transfusion
Liberal red blood cell transfusion increases circulating hemoglobin and oxygen-carrying capacity by administering donor red blood cells to patients with anemia or blood loss.
Liberal red blood cell transfusion increases circulating hemoglobin and oxygen-carrying capacity by administering donor red blood cells to patients with anemia or blood loss. Used for Anemia in critically ill patients, Perioperative blood loss management.
At a glance
| Generic name | Liberal Red blood cell transfusion |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Blood product / Cellular therapy |
| Modality | Biologic |
| Therapeutic area | Hematology / Critical Care / Perioperative Medicine |
| Phase | Phase 3 |
Mechanism of action
This is a blood product transfusion strategy that aims to maintain higher hemoglobin levels (typically >10 g/dL) compared to restrictive transfusion strategies. The transfused red blood cells restore oxygen delivery to tissues and improve tissue perfusion in critically ill or perioperative patients.
Approved indications
- Anemia in critically ill patients
- Perioperative blood loss management
Common side effects
- Transfusion-related acute lung injury (TRALI)
- Febrile non-hemolytic transfusion reaction
- Allergic reaction
- Hemolytic transfusion reaction
- Transfusion-associated circulatory overload (TACO)
- Infection transmission risk
Key clinical trials
- Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia (NA)
- Transfusion of Prematures Trial (NA)
- Liberal Transfusion Strategy in Elderly Patients (PHASE3)
- Hemoglobin Levels for Blood Transfusions During and After Surgery (NA)
- Oxygen Extraction-guided Transfusion (NA)
- Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer (EARLY_PHASE1)
- Red Blood Cell Transfusion in ECMO - A Feasibility Trial (NA)
- Effect of Giving Reduced Fluid in Children After Trauma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: